金河生物(002688) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥462,170,158.21, representing a 6.73% increase compared to ¥433,027,256.62 in the same period last year[7]. - Net profit attributable to shareholders was ¥85,425,834.34, a significant increase of 57.97% from ¥54,075,869.30 year-over-year[7]. - The net profit after deducting non-recurring gains and losses was ¥63,697,503.71, up 19.81% from ¥53,166,354.15 in the previous year[7]. - The basic earnings per share increased by 44.44% to ¥0.13 from ¥0.09 in the same period last year[7]. - The company's net profit margin improved significantly, reflecting a strong operational performance and effective cost management strategies[20]. - The company reported a total comprehensive income of CNY 98,859,141.70 for Q1 2021, compared to CNY 66,181,077.77 in the previous year, marking an increase of approximately 49.5%[53]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,660,920,295.03, an increase of 8.41% from ¥3,376,867,194.00 at the end of the previous year[7]. - Total liabilities rose to ¥1,812,698,017.30 from ¥1,626,925,856.12, reflecting an increase of about 11.4%[43]. - The company's equity attributable to shareholders increased to ¥1,701,959,012.78 from ¥1,614,883,310.48, representing a growth of approximately 5.4%[44]. - Current assets increased to ¥1,471,015,962.11 as of March 31, 2021, up from ¥1,240,147,130.98 on December 31, 2020, representing a growth of approximately 18.6%[41]. - Total assets reached ¥3,660,920,295.03, up from ¥3,376,867,194.00, indicating an increase of about 8.4%[44]. Cash Flow - The net cash flow from operating activities was negative at -¥25,322,456.62, a drastic decline from ¥169,026.42 in the same period last year, representing a decrease of 15,081.36%[7]. - Cash received from operating activities increased by ¥8,293,766.36, a rise of 169.89%, mainly due to the return of previously paid land compensation[22]. - Cash flow from investing activities showed a net outflow increase of ¥35,758,681.30, a rise of 111.87%, primarily due to the concentrated procurement phase of the vaccine base construction project[24]. - Cash flow from financing activities increased by ¥67,169,988.99, a rise of 60.61%, due to increased reserves for operational needs and changes in borrowing models[24]. Shareholder Information - The total number of shareholders at the end of the reporting period was 36,906, indicating a stable shareholder base[11]. - The controlling shareholder, Inner Mongolia Jinhai Construction and Installation Co., Ltd., underwent a division, transferring 241,758,670 shares to Inner Mongolia Jinhai Holdings Co., Ltd.[25]. Research and Development - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[45]. - Research and development expenses for Q1 2021 were CNY 17,370,744.69, up from CNY 14,920,829.51, indicating a focus on innovation[51]. Regulatory and Compliance - The company received approval from the China Securities Regulatory Commission for a non-public stock issuance on December 11, 2020[25]. - There were no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[29]. - The company reported no securities or derivative investments during the reporting period[30][31]. - There were no violations regarding external guarantees during the reporting period[34]. - The company did not engage in any entrusted financial management during the reporting period[33]. - The company has not undergone an audit for the first quarter report[72].